Mather Group LLC. Has $581,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Mather Group LLC. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 19.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,946 shares of the company’s stock after selling 692 shares during the period. Mather Group LLC.’s holdings in Zoetis were worth $581,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Silver Oak Securities Incorporated acquired a new stake in Zoetis during the 4th quarter worth about $266,000. Gitterman Wealth Management LLC purchased a new stake in shares of Zoetis in the fourth quarter worth approximately $292,000. Legacy Capital Wealth Partners LLC boosted its holdings in shares of Zoetis by 7.5% during the fourth quarter. Legacy Capital Wealth Partners LLC now owns 1,363 shares of the company’s stock worth $269,000 after purchasing an additional 95 shares during the period. Paradigm Financial Partners LLC grew its position in Zoetis by 2.1% during the fourth quarter. Paradigm Financial Partners LLC now owns 14,806 shares of the company’s stock valued at $2,922,000 after purchasing an additional 304 shares in the last quarter. Finally, PGGM Investments increased its stake in Zoetis by 2.7% in the 4th quarter. PGGM Investments now owns 28,473 shares of the company’s stock valued at $5,620,000 after buying an additional 758 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.4 %

Zoetis stock opened at $158.53 on Thursday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The company has a market capitalization of $72.51 billion, a price-to-earnings ratio of 31.27, a PEG ratio of 2.50 and a beta of 0.86. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company’s fifty day moving average price is $170.07 and its two-hundred day moving average price is $178.97.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.15 earnings per share. On average, analysts forecast that Zoetis Inc. will post 5.78 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now directly owns 15,723 shares in the company, valued at $2,725,267.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 2,209 shares of company stock worth $371,293 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ZTS shares. Stifel Nicolaus decreased their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday. Piper Sandler restated an “overweight” rating and issued a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Barclays lowered their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Finally, The Goldman Sachs Group raised their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $216.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.